Gene Mack

CIK: 0001737979

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GANX

Gain Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

GANX
Gain Therapeutics, Inc.
Mar 24, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
200K shares-
GANX
Gain Therapeutics, Inc.
Mar 20, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
200K shares-
GANX
Gain Therapeutics, Inc.
Jan 6, 2025
Award(A)
Stock Option (right to buy)
Direct
271.3K shares-

		Type	Shares	Price		Ownership
Mar 24, 2026	GANX Gain Therapeutics, Inc.	Award(A) Employee Stock Option (right to buy)	200,000	-	-	Direct
Mar 20, 2025	GANX Gain Therapeutics, Inc.	Award(A) Employee Stock Option (right to buy)	200,000	-	-	Direct
Jan 6, 2025	GANX Gain Therapeutics, Inc.	Award(A) Stock Option (right to buy)	271,325	-	-	Direct

1-3 of 3 transactions

About Mack Gene

Mack Gene (SEC CIK 0001737979) files insider reports with the SEC as CEO, President of Gain Therapeutics, Inc. (GANX).

Signal8 holds 3 ownership filings by Mack Gene, all Form 4s, filed between Jan 7, 2025 and Mar 26, 2026. Those filings report 3 transactions, from Jan 6, 2025 to Mar 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mack Gene's filings is in BETHESDA, MD.

Recent filings by Mack Gene

Mar 24, 2026: Grant or award of GANX derivative securities (Form 4, code A).
Mar 20, 2025: Grant or award of GANX derivative securities (Form 4, code A).
Jan 6, 2025: Grant or award of GANX derivative securities (Form 4, code A).

Other insiders filing for Gain Therapeutics, Inc. (GANX)

How to read Form 4 transaction codes